Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review

BACKGROUND: The neoadjuvant use of immune checkpoint inhibitors (ICIs) in resectable non-small-cell lung cancer (NSCLC) is currently an area of active ongoing research. The place of neoadjuvant ICIs in the treatment guidelines needs to be determined. We carried out a systematic review of published d...

Descripción completa

Detalles Bibliográficos
Autores principales: Ulas, E.B., Dickhoff, C., Schneiders, F.L., Senan, S., Bahce, I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8414043/
https://www.ncbi.nlm.nih.gov/pubmed/34479033
http://dx.doi.org/10.1016/j.esmoop.2021.100244

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8414043/
https://www.ncbi.nlm.nih.gov/pubmed/34479033
http://dx.doi.org/10.1016/j.esmoop.2021.100244

Ejemplares similares